Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Submits Paliperidone ER

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson submitted an NDA Nov. 29 for its Risperdal follow-on paliperidone extended-release, the firm said Nov. 30

You may also be interested in...



Paliperidone “Approvable” Puts Pressure On J&J Evergreening Strategy

While not unexpected, the regulatory delay means the company will have less time to transition patients to the Risperdal follow-on.

Paliperidone “Approvable” Puts Pressure On J&J Evergreening Strategy

While not unexpected, the regulatory delay means the company will have less time to transition patients to the Risperdal follow-on.

J&J Paliperidone ER To Go Before Advisory Panel Weeks Before User Fee Date

The firm could have an eight-month lead over AstraZeneca’s once-a-day antidepressant.

Related Content

Topics

UsernamePublicRestriction

Register

PS061337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel